12:00 AM
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Jetrea ocriplasmin regulatory update

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet on July 26 to discuss a BLA from ThromboGenics for ocriplasmin intravitreal injection to treat symptomatic vitreomacular adhesion. Earlier this month, ThromboGenics...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >